X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop a CLDN18.2 companion diagnostic to support phase III of TST001 (osemitamab) in combination with nivolumab and chemotherapy in patients with CLDN18.2 expressing locally advanced or metastatic gastroesophageal adenocarcinoma.
Lead Product(s): Osemitamab,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Transcenta Holding
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 08, 2024
Details:
Based on results, Verzenio may require dose modification. Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. Advise patients of potential risk to a fetus and to use effective contraception.
Lead Product(s): Abemaciclib,Tamoxifen Citrate
Therapeutic Area: Oncology Product Name: Verzenio
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
The MOU establishes a framework in which the two companies will enter into a strategic partnership to explore potential genomic biomarkers of the tumor microenvironment in an early-phase trial of the investigational compound GI-101.
Lead Product(s): GI-101,Pembrolizumab
Therapeutic Area: Oncology Product Name: GI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: GI Innovation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
